Sei Investments Co. Grows Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Sei Investments Co. increased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 6.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 673,868 shares of the medical research company's stock after acquiring an additional 38,827 shares during the period. Sei Investments Co. owned about 1.32% of Charles River Laboratories International worth $124,394,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Fiduciary Financial Group LLC increased its holdings in shares of Charles River Laboratories International by 3.9% during the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock valued at $310,000 after purchasing an additional 63 shares in the last quarter. Pinnacle Bancorp Inc. grew its stake in Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after acquiring an additional 65 shares during the period. M&T Bank Corp increased its stake in shares of Charles River Laboratories International by 3.4% during the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock worth $394,000 after purchasing an additional 66 shares in the last quarter. Cornerstone Investment Partners LLC raised its position in shares of Charles River Laboratories International by 3.7% during the 4th quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company's stock worth $358,000 after purchasing an additional 69 shares during the last quarter. Finally, Metis Global Partners LLC lifted its stake in Charles River Laboratories International by 4.4% in the 4th quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company's stock valued at $318,000 after buying an additional 72 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

Several equities research analysts have commented on CRL shares. Bank of America reduced their target price on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a report on Friday, December 13th. UBS Group reissued a "neutral" rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. JPMorgan Chase & Co. dropped their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a report on Thursday, February 20th. Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 5th. Finally, Robert W. Baird dropped their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a research note on Thursday, February 20th. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $189.77.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO James C. Foster acquired 6,075 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the acquisition, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Trading Down 3.2 %

Shares of CRL traded down $5.41 during trading on Tuesday, reaching $161.57. 466,141 shares of the company traded hands, compared to its average volume of 724,610. The stock has a 50-day simple moving average of $165.66 and a 200-day simple moving average of $183.49. The stock has a market cap of $8.26 billion, a PE ratio of 1,077.13, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $273.57. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same quarter last year, the firm earned $2.46 EPS. The firm's revenue for the quarter was down 1.1% on a year-over-year basis. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).